Saskatchewan patients eligible for new cystic fibrosis drug Alyftrek

Cystic fibrosis patients in Saskatchewan now have access to a new drug to help control their symptoms and slow the disease’s progression.

According to the Saskatchewan Ministry of Health, Alyftrek is now available to cystic fibrosis patients aged six and older in the province who meet the medical criteria.

Read more:

• Health authority adding security staff to facilities in five more Saskatchewan communities
• Court finds B.C.’s involuntary mental health treatment scheme unconstitutional
• Province provides update, reports progress on Sask. health-care recruitment

The ministry said the drug is effective for patients with one of 266 genetic mutations that cause cystic fibrosis. The coverage comes after a recommendation made by Health Canada in July 2025, which was followed by pricing negotiations last month.

“Our government is pleased to cover the cost of this new treatment for Saskatchewan patients with cystic fibrosis,” Saskatchewan Health Minister Jeremy Cockrill said in a statement.

“Alyftrek has been shown to improve quality of life in patients with CF, so expanding coverage puts CF patients first by helping them to lead healthier lives.”

Cystic fibrosis is a genetic disease that damages both the lungs and the digestive system. The ministry said there are more than 4,500 people in Canada living with the condition, and nearly 150 of them live in Saskatchewan.

Patients with cystic fibrosis, or parents of children with the condition, were encouraged to talk to their doctor if they think they would benefit from Alyftrek.